This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NeoStem's CEO Robin Smith Gives 'The Stock Radio' An Update On The Company

NEW YORK, Oct. 4, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy market, gives an update on the Company's progress from the 'NIBA' convention recently held in New York City: http://thestockradio.com/robin-smith-ceo-of-neostem-inc-amexnbs/1538 .

In summary, NeoStem listed on the NYSE MKT, is emerging as a leading cell therapy company that:        

Has an Exciting Proprietary Cell Therapy Pipeline
  •  Phase 2 AMR-001 PreSERVE trial enrollment completion and data read-out expected in 2013

-- Patient accrual is underway

-- Strong IP portfolio in a rapidly growing industry

-- $50 billion is spent annually on regenerative medicine

-- Industry projected to increase 15% annually (compounded)

Generates Revenue from Contract Development and Manufacturing Business
  • Revenue side of the business averaging >$10 million annually
  • Validation of approach through agreements with "Who's Who" of cell therapy companies

Has a Leadership That Can Execute
  • Strong management team with decades of regulatory experience
  • Successfully completed five M&A transactions
  • Obtained $3 million in DOD and NIH funding to advance cell therapy products
  • Submitted an additional $13 million in grant applications

Has a Known Presence and Strong Performance on the Street
  • Consistent liquidity and strong technical indicators
  • Returns of ~24% since July, outperforming the NASDAQ (+5.3%) and S&P 500 (+5.7%) averages
  • Respected analyst coverage: Cowen, JMP and WBB

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,550.69 -47.51 -0.27%
S&P 500 2,093.32 -4.72 -0.22%
NASDAQ 5,105.5460 -9.8360 -0.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs